These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28436941)

  • 1. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.
    Hu JL; Hu XL; Han Q; Guo AY; Wang CJ; Wen YY; Cang SD
    Gene Ther; 2017 Jul; 24(7):392-398. PubMed ID: 28436941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Association between single nucleotide polymorphism of rs2252673 of INSR gene and polycystic ovarian syndrome].
    Du J; Wang Z; Zhang J; Jia L; Zhang F; Shi Y; Chen Z
    Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):919-24. PubMed ID: 25608993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.
    Li Y; Zhang HL; Kang S; Zhou RM; Wang N
    Gynecol Oncol; 2017 Jan; 144(1):140-145. PubMed ID: 27836206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
    Li Y; Hu P; Cao Y; Wang GY; Wang N; Zhou RM
    Biomarkers; 2014 Mar; 19(2):128-34. PubMed ID: 24499239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
    Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.
    Liu BL; Liu SJ; Baskys A; Cheng H; Han Y; Xie C; Song H; Li J; Xin XY
    BMC Cancer; 2014 Nov; 14():829. PubMed ID: 25399490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.
    Permuth-Wey J; Fulp WJ; Reid BM; Chen Z; Georgeades C; Cheng JQ; Magliocco A; Chen DT; Lancaster JM
    Int J Cancer; 2016 Feb; 138(3):612-9. PubMed ID: 26264211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.
    Yan L; Shu-Ying Y; Shan K; Yip BH; Rong-Miao Z; Na W; Hai-Yan S
    Pharmacogenomics; 2012 Mar; 13(4):419-27. PubMed ID: 22329723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients.
    Camerin GR; Brito AB; Vassallo J; Derchain SF; Lima CS
    Future Oncol; 2017 Feb; 13(5):409-414. PubMed ID: 27780361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
    Wang Y; Li M; Meng F; Lou G
    Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer.
    Lin K; Ye D; Xie X
    Int J Gynecol Cancer; 2008; 18(5):1007-12. PubMed ID: 18081788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
    Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.
    Li Y; Hao YL; Kang S; Zhou RM; Wang N; Qi BL
    Gynecol Oncol; 2013 Mar; 128(3):584-9. PubMed ID: 23234803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
    Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
    Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
    Mariya T; Hirohashi Y; Torigoe T; Asano T; Kuroda T; Yasuda K; Mizuuchi M; Sonoda T; Saito T; Sato N
    Cancer Immunol Res; 2014 Dec; 2(12):1220-9. PubMed ID: 25324403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.